Hot Investor Mandate: Corporate Venture Arm of Large Healthcare Company Invests in Novel Therapeutics & Diagnostics With Strong Strategic Fit

5 Nov

A corporate venture fund of a large healthcare company has allocated over $500 million to invest in and develop commercially successful innovative life science companies. This evergreen fund is financially driven and reporting into the finance organization, rather than being a strategic vehicle. The fund makes equity investment in early-stage biotech therapeutic and diagnostic companies. The fund prefers Series A. The typical initial investment size ranges from CHF 1-5M with capital reserved for follow-on financing. The fund invests in companies that are based in Europe, North America, and the Pacific Region.

The firm invests in companies with innovative new technologies, medicines or diagnostics, particularly in the areas of interest to the parent company. This includes: Oncology, Central Nervous System, Inflammation, Anti-Infectives, Virology, in-Vitro Diagnostics, Diabetes Care, and Molecular Diagnostics. For therapeutic biotech, the fund is willing to invest in companies that are still 18-24 months away from the clinic. The fund highly prefers companies with both a discovery engine and a product pipeline.

The firm invests in private and public companies. The fund requests board seats and typically prefers to be in an ownership range of 15% or more. In general, the fund prefers to co-invest with leading venture funds as well as other corporate venture funds.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: